Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the first participant has been dosed in a Phase 1 trial of EDP-978, an oral once-daily KIT inhibitor in development for chronic urticaria and other mast cell-driven diseases.
The randomized, double-blind, placebo-controlled SAD and MAD study will enroll approximately 98 healthy adults (18–65). The MAD includes a 14-day treatment period and the SAD includes a two-part food-effect cohort. Topline Phase 1 data, including serum tryptase biomarker effects, are expected in Q4 2026.
Enanta Pharmaceuticals (NASDAQ:ENTA) will present new clinical data for zelicapavir, an oral once-daily N‑protein inhibitor for RSV, at ESCMID Global 2026 on April 18, 2026 in Munich.
Presentations include Phase 2b high-risk adult results showing ~one week faster symptom resolution and lower hospitalization, plus pediatric data confirming a high barrier to antiviral resistance and strong exposure multiples over EC90.
Enanta Pharmaceuticals (NASDAQ: ENTA) will present four preclinical posters on its STAT6 inhibitor program at IMMUNOLOGY2026, April 15-19, 2026, in Boston. Presentations cover EPS-3903 tolerability, selectivity, pharmacokinetics, and activity in asthma and allergic disease models.
Each poster lists date, time, session, and presenters; posters will be posted on the company website after each presentation.
Enanta Pharmaceuticals (NASDAQ:ENTA) said members of management will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026 at 10:45 a.m. ET in Miami Beach, FL.
According to Enanta, a live webcast will be available via the company’s Investors "Events and Presentations" page and a replay will be archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) will present preclinical data for EDP-978, its KIT inhibitor candidate for mast cell-mediated, Type 2 immune diseases, in two poster sessions at the 2026 AAAAI Annual Meeting in Philadelphia on February 27, 2026.
Posters (Numbers 104 and 038) in the Allergic Skin Diseases session are scheduled 2:45–3:45 PM EST and will be available on Enanta's website after the presentations; abstracts appear in the JACI online supplement.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported fiscal Q1 results for the quarter ended December 31, 2025 and highlighted progress across virology and immunology programs.
Key items: $241.9M in cash and marketable securities, ongoing Phase 3 enabling activities for zelicapavir, IND plans for EDP-978 and EPS-3903, and a new MRGPRX2 program with candidate selection targeted in 2H 2026.
Summary not available.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 3:00 p.m. PT in San Francisco.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.enanta.com, and a replay will be archived for at least 30 days following the presentation.
Summary not available.
Enanta Pharmaceuticals (NASDAQ:ENTA) said company management will participate in investor conferences in November and December 2025. Jefferies London Global Healthcare Conference fireside chat is scheduled for Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET. Evercore Healthcare Conference fireside chat is scheduled for Wednesday, December 3, 2025 at 8:20 a.m. ET.
A live webcast of each event will be available on the company’s Investors page under Events and Presentations at www.enanta.com, with replays archived for at least 30 days.